6-Cyclo­hexyl­meth­yl-5-ethyl-2-[(2-oxo-2-phenyl­eth­yl)sulfan­yl]pyrimidin-4(3H)-one

In the title compound, C(21)H(26)N(2)O(2)S, the cyclo­hexane ring adopts a chair conformation. The angle at the methyl­ene bridge linking the pyrimidine and cyclo­hexane rings is 113.41 (13)°. This is in the range considered optimal for maximum activity of non-nucleoside reverse transcriptase inhibi...

Descripción completa

Detalles Bibliográficos
Autores principales: Yan, Wan-Lu, Guo, Qiong, Li, Cong, Ji, Xiao-Ying, He, Yan-Ping
Formato: Texto
Lenguaje:English
Publicado: International Union of Crystallography 2011
Materias:
Organic Papers
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3051611/
https://www.ncbi.nlm.nih.gov/pubmed/21523182
http://dx.doi.org/10.1107/S1600536811003175
Descripción
Sumario:In the title compound, C(21)H(26)N(2)O(2)S, the cyclo­hexane ring adopts a chair conformation. The angle at the methyl­ene bridge linking the pyrimidine and cyclo­hexane rings is 113.41 (13)°. This is in the range considered optimal for maximum activity of non-nucleoside reverse transcriptase inhibitors. In the crystal, mol­ecules are connected into centrosymmetric dimers via pairs of N—H⋯O hydrogen bonds.

Ejemplares similares